Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol. 2022;7(8):700.
   PubMed Web of Science ®Google Scholar
• Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–928. doi:10.1002/bjs.8702.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• Li Y, Pan Y, Lin X, Hou J, Hu Z, Xu L, et al. Development and validation of a prognostic score for hepatocellular carcinoma patients in immune checkpoint inhibitors therapies: the hepatocellular carcinoma modified Gustave Roussy Immune score. Front Pharmacol. 2021;12:819985. doi:10.3389/fphar.2021.819985.
   PubMed Web of Science ®Google Scholar
• Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, et al. The Gustave Roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. J Clin Med. 2021;10(5):1005.
   PubMed Web of Science ®Google Scholar
• Nakazawa N, Sohda M, Ubukata Y, Kuriyama K, Kimura A, Kogure N, et al. Changes in the Gustave Roussy immune score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: a multicenter, retrospective study. Ann Surg Oncol. 2022;29(12):7400–7406. doi:10.1245/s10434-022-12226-4.
   PubMed Web of Science ®Google Scholar
• Tian S, Cao Y, Duan Y, Liu Q, Peng P. Gustave Roussy immune score as a novel prognostic scoring system for colorectal cancer patients: a propensity score matching analysis. Front Oncol. 2021;11:737283. doi:10.3389/fonc.2021.737283.
   PubMedGoogle Scholar
• Chiloiro G, Romano A, Mariani S, Macchia G, Giannarelli D, Caravatta L, et al. Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) – a multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) gastrointestinal study group. Clin Transl Radiat Oncol. 2023;39:100579.
   PubMed Web of Science ®Google Scholar
• Guan B, Huang X, Xia H, Guan G, Xu B. Prognostic value of mesorectal package area in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: a retrospective cohort study. Front Oncol. 2022;12:941786. doi:10.3389/fonc.2022.941786.
   PubMed Web of Science ®Google Scholar
• Portale G, Cavallin F, Valdegamberi A, Frigo F, Fiscon V. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio are not prognostic biomarkers in rectal cancer patients with curative resection. J Gastrointest Surg. 2018;22(9):1611–1618. doi:10.1007/s11605-018-3781-2.
   PubMed Web of Science ®Google Scholar
• Yang B, Shan J, Feng Y, Dai N, Li M, Chen C, et al. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study. Radiat Oncol. 2020;15(1):94. doi:10.1186/s13014-020-01540-4.
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. doi:10.1001/jamaoncol.2017.4771.
   PubMed Web of Science ®Google Scholar
• Ryu HS, Lee JL, Kim CW, Yoon YS, Park IJ, Lim SB, et al. Correlative significance of tumor regression grade and ypT category in patients undergoing preoperative chemoradiotherapy for locally advanced rectal cancer. Clin Colorectal Cancer. 2022;21(3):212–219. doi:10.1016/j.clcc.2022.02.001.
   PubMed Web of Science ®Google Scholar
• Jäger T, Neureiter D, Urbas R, Klieser E, Hitzl W, Emmanuel K, et al. Applicability of American Joint Committee on cancer and College of American Pathologists regression grading system in rectal cancer. Dis Colon Rectum. 2017;60(8):815–826. doi:10.1097/DCR.0000000000000806.
   PubMed Web of Science ®Google Scholar
• Bong JW, Lim SB, Ryu H, Lee JL, Kim CW, Yoon YS, et al. Effect of anaemia on the response to preoperative chemoradiotherapy for rectal cancer. ANZ J Surg. 2021;91(5):E286–E291. doi:10.1111/ans.16547.
   PubMed Web of Science ®Google Scholar
• Rodrigues D, Simões J, Teixeira L, Aires F, Fernandes C, Rey C, et al. Baseline anaemia increases locally advanced rectal cancer mortality in older patients undergoing preoperative chemoradiation. Support Care Cancer. 2021;29(3):1403–1411. doi:10.1007/s00520-020-05618-3.
   PubMed Web of Science ®Google Scholar
• Cosper PF, McNair C, González I, Wong N, Knudsen KE, Chen JJ, et al. Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. Int J Cancer. 2020;146(7):2047–2058. doi:10.1002/ijc.32793.
   PubMed Web of Science ®Google Scholar
• Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022;40(2):168–184 e13. doi:10.1016/j.ccell.2022.01.004.
   PubMed Web of Science ®Google Scholar
• Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H, et al. Nasopharyngeal carcinoma: current views on the tumor microenvironment’s impact on drug resistance and clinical outcomes. Mol Cancer. 2024;23(1):20. doi:10.1186/s12943-023-01928-2.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503–e503. doi:10.1016/S1470-2045(14)70263-3.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li J, Peng Q, Huang Y, Tang L, Zhuang Q, et al. Association of markers of systemic and local inflammation with prognosis of patients with rectal cancer who received neoadjuvant radiotherapy. Cancer Manag Res. 2019;11:191–199. doi:10.2147/CMAR.S187559.
   PubMed Web of Science ®Google Scholar
• Dudani S, Marginean H, Tang PA, Monzon JG, Raissouni S, Asmis TR, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer. 2019;19(1):664. doi:10.1186/s12885-019-5892-x.
   PubMedGoogle Scholar
• Lai S, Huang L, Luo S, Liu Z, Dong J, Wang L, et al. Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol Lett. 2020;20(3):2763–2770. doi:10.3892/ol.2020.11812.
   PubMed Web of Science ®Google Scholar
• Gawiński C, Mróz A, Roszkowska-Purska K, Sosnowska I, Derezińska-Wołek E, Michalski W, et al. A prospective study on the roles of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in patients with locally advanced rectal cancer. Biomedicines. 2023;11(11):3048. doi:10.3390/biomedicines11113048.
   PubMed Web of Science ®Google Scholar
• Eraslan E, Adas YG, Yildiz F, Gulesen AI, Karacin C, Arslan UY. Systemic immune-inflammation index (SII) predicts pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. J Coll Physicians Surg Pak. 2021;31 (4):399–404. doi:10.29271/jcpsp.2021.04.399.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen L, Zhang B, Song W, Zhou G, Xie L, et al. Pretreatment inflammatory-nutritional biomarkers predict responses to neoadjuvant chemoradiotherapy and survival in locally advanced rectal cancer. Front Oncol. 2021;11:639909. doi:10.3389/fonc.2021.639909.
   PubMed Web of Science ®Google Scholar
• Arıkan R, Alkış H, Işık S, Yaşar A, Çelebi A, Majidova N, et al. Evaluation of predictive and prognostic importance of lung immune prognostic index in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy. Cureus. 2023;15(6):e40548. doi:10.7759/cureus.40548.
   PubMed Web of Science ®Google Scholar
• Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181–193. doi:10.1002/jpen.1451.
   PubMed Web of Science ®Google Scholar
• Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19(12):749–762. doi:10.1038/s41571-022-00686-2.
   PubMed Web of Science ®Google Scholar
• Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6):e004688. doi:10.1136/jitc-2022-004688.
   PubMed Web of Science ®Google Scholar
• Feng JF, Wang L, Yang X, Chen S. Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma. J Cancer. 2020;11(6):1334–1340.
   PubMed Web of Science ®Google Scholar
• Li SJ, Zhao L, Wang HY, Zhou HN, Ju J, Du H, et al. Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: a propensity score matching retrospective cohort study. Int J Surg. 2020;84:25–40.
   PubMed Web of Science ®Google Scholar
• Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M, Fuereder T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med. 2022;54(1):1339–1349.
   PubMed Web of Science ®Google Scholar